Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Murgo

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2005
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphomaQin C Ryan, Donna Headlee, Milin Acharya, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2007
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemiaWilliam Blum, Rebecca B Klisovic, Bjoern Hackanson, et al.
Leukemia Research|July 6, 2010
Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSFB Douglas Smith, Richard J Jones, Eunpi Cho, et al.
Cancer Research|June 17, 2006
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasmsSteven D Gore, Stephen Baylin, Elizabeth Sugar, et al.
Neuro-Oncology|February 13, 2007
Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium reportIan F Pollack, Regina I Jakacki, Susan M Blaney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 6, 2012
Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summaryKatherine Thornton, Geoffrey Kim, V Ellen Maher, et al.
Blood|June 24, 2009
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignanciesTamer E Fandy, James G Herman, Patrick Kerns, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2005
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphomaQin C Ryan, Donna Headlee, Milin Acharya, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2007
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemiaWilliam Blum, Rebecca B Klisovic, Bjoern Hackanson, et al.
Leukemia Research|July 6, 2010
Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSFB Douglas Smith, Richard J Jones, Eunpi Cho, et al.
Cancer Research|June 17, 2006
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasmsSteven D Gore, Stephen Baylin, Elizabeth Sugar, et al.
Neuro-Oncology|February 13, 2007
Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium reportIan F Pollack, Regina I Jakacki, Susan M Blaney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 6, 2012
Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summaryKatherine Thornton, Geoffrey Kim, V Ellen Maher, et al.
Blood|June 24, 2009
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignanciesTamer E Fandy, James G Herman, Patrick Kerns, et al.
Pageof 2